Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

When governments collude…

Rhode Island Democrats Move to Double State Income Taxes on Unvaccinated Residents

https://dailyclout.io/?s=Rhode+Island+

According to the Blaze’s Daniel Horowitz, the FDA allowed aviptadil to be prescribed to treat patients with Acute respiratory distress syndrome (ARDS) under the “orphan drug designation” way back in 2001. Orphan drugs are pharmaceutical agents that are not profitable because they treat rare medical conditions, and thus require government assistance to produce. They are used to treat life-threatening or chronically debilitating conditions affecting less than 200,000 patients.
Aviptadil was also awarded the orphan drug destination for pulmonary arterial hypertension in 2005, and for pulmonary sarcoidosis in 2021, Horowitz reported. Unfortunately, it has never been fully approved by the FDA.

https://amgreatness.com/2022/03/09/in-letter-to-fda-and-niaid-ron-johnson-demands-to-know-why-promising-late-stage-covid-drug-was-never-approved/

MIT Scientist Links Covid Vax and Severe Disease

https://rumble.com/vsxgyr-mit-scientist-links-covid-vax-and-severe-disease-5880.html

Neurodegenerative disorders (NDDs) are characterized by neuronal death in the brain. The mechanism of the neuronal death is too complicated to be fully understood, although in many NDDs, aging and neurotoxins are known risk factors. In the central and peripheral nervous system, vasoactive intestinal peptide (VIP), a 28-amino acid neuropeptide, is released to support neuronal survival in both physiological and pathological condition. VIP can inhibit the neurodegeneration induced by the loss of neurons. The indirect protection effect is mainly mediated by glial cells through the production of neurotrophic factor(s) and inhibition of proinflammatory mediators. By remolding the structure and improving the transfer efficiency of VIP, its nerve protective function could be further improved. Its neuroprotective action and efficacy in inhibiting a broad range of inflammatory responses make VIP or related peptides becoming a novel therapeutic method to NDDs. In this review, we aim to summarize the relationship between VIP and NDDs.

https://pubmed.ncbi.nlm.nih.gov/27786097/

Because of its lack of toxicity and low cost of manufacture compared to proprietary biologics, VIP may be uniquely attractive to those focused on global countermeasures against COVID-19

https://www.precisionvaccinations.com/vaccines/zyesami-aviptadil-therapeutic

Write to the U.S. Congress for approval of AVIPTADIL, now!!